Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 56

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 56
---
itation of an offer to buy any securities other than the securities described
in this prospectus or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer
or solicitation is unlawful.

For investors outside the United States: Neither
we nor any underwriters, dealers or agents have taken any action that would permit the offering or possession or distribution of this
prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United
States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering
of the securities described herein and the distribution of this prospectus outside the United States.

Unless otherwise noted or the context otherwise requires, references
in this prospectus to “Alpha Tau,” “the Company,” “our company,” “we,” “us”
or “our” refer to Alpha Tau Medical Ltd. and its subsidiaries.

<div align='center'>1

ABOUT THE COMPANY</div>

We are a clinical-stage oncology therapeutics
company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation
therapy for solid tumors. Our proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles
while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation’s limited range.
We believe that our Alpha DaRT technology has the potential to be broadly applicable across multiple targets and tumor types. We have
evaluated and continue to evaluate the feasibility, safety and efficacy of the Alpha DaRT technology for the treatment of superficial
lesions, i.e., tumors of the skin, head or neck, in multiple clinical trials conducted in clinical sites around the world. In a first-in-human
study of locally advanced and recurrent squamous cell carcinoma, or SCC, cancers of the skin and head and neck, efficacy was evaluated
in 28 tumors, and results showed that Alpha DaRT achieved 100% overall response rate and over 78% complete response rate. The Alpha DaRT
was generally well-tolerated, with limited local toxicity and no systemic toxicity. On the basis of this clinical trial as well as some
of our further clinical trials, we received marketing approval in Israel in August 2020 for the treatment of SCC of the skin or oral cavity
using the Alpha DaRT. In June 2021, the FDA granted the Alpha DaRT Breakthrough Device Designation